TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7758229
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement therapy (0.04 +/- 0.01 IU/kg daily) for 18 months
Study: 2139340
Drug: Xamoterol 100
Normalized name: Xamoterol
DrugBank: Xamoterol (DB13781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol 100 mg
Study: 2139340
Drug: Xamoterol 100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol 100, 200, or 300 mg
Study: 2139340
Drug: Xamoterol (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol (various doses)
Study: 7000149
Drug: i.v. BCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. BCG immunotherapy
Study: 7000149
Drug: Immunotherapy (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (both groups)
Study: 27697801
Drug: ivabradine 7.5
Normalized name: ivabradine 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine 7.5 mg twice per day
Study: 24773830
Drug: OM-85 (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM-85 (7 mg, one daily capsule taken orally for 10 days each month for 3 consecutive months)
Study: 22676715
Drug: PDX/GOS (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDX/GOS (4 g/L prebiotic blend of polydextrose and galactooligosaccharides)
Study: 22676715
Drug: GOS (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOS (4 g/L galactooligosaccharides)
Study: 16335040
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide bleaching gel (Perfect Bleach)
Study: 16335040
Drug: 16% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16% carbamide peroxide bleaching gel (Viva Style)
Study: 10403690
Drug: Supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive care plus combination chemotherapy (IEP regimen: ifosfamide 3 gm/m2 IV with mesna uroprotection, epirubicin 60 mg/m2 IV on day 1 and cisplatin 60 mg/m2 IV on day 2)
Study: 10403690
Drug: Supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive care plus combination chemotherapy (MVP regimen: mitomycin-C 8 mg/m2, cisplatin 100 mg/m2 IV on day 1, vinblastine 4 mg/m2 IV on days 1 and 15)
Study: 7720887
Drug: Postoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiotherapy and doxorubicin‐based chemotherapy with tamoxifen
Study: 7720887
Drug: Postoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiotherapy and doxorubicin‐based chemotherapy without tamoxifen
Study: 30701884
Drug: Canakinumab (monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab (monoclonal antibodies to IL-1β)
Study: 26585409
Drug: Antipsychotic review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic review plus social interaction intervention
Study: 26585409
Drug: Antipsychotic review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic review without social intervention
Study: 18161400
Drug: Etoricoxib, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib, 120 mg
Study: 18161400
Drug: Mefenamic acid,
Normalized name: Mefenamic Acid, 250 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefenamic acid, 500 mg every 8 hours
Study: 9040452
Drug: Reserpine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reserpine (0.1 mg) plus thiazide clopamid (5 mg)
Study: 9040452
Drug: Reserpine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reserpine (0.1 mg)
Study: 9040452
Drug: Thiazide clopamid
Normalized name: clopamide
DrugBank: Clopamide (DB13792)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide clopamid (5 mg)
Study: 8174419
Drug: fedotozine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: fedotozine 30 mg three times a day
Study: 8174419
Drug: fedotozine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: fedotozine 30 mg and 70 mg
Study: 8174419
Drug: fedotozine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: fedotozine (all doses)
Study: 3217992
Drug: Cisplatin (P)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (P) 60 mg/m2/day on days 1 and 2 every 28 days
Study: 3217992
Drug: CAP (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP (cyclophosphamide 750 mg/m2, adriamycin 50 mg/m2, cisplatin 50 mg/m2 on day 1 every 21 days)
Study: 900585
Drug: Fenoterol metered-dose
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol metered-dose inhaler
Study: 900585
Drug: Isoproterenol metered-dose
Normalized name: isoproterenol hydrochloride Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol metered-dose inhaler
Study: 30926293
Drug: Topical vibratory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vibratory stimulation (100-Hz vibration applied to the popliteal fossa for 3 to 5 seconds prior to and during TPI)
Study: 30926293
Drug: Topical vibratory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vibratory stimulation
Study: 19829284
Drug: Anti-diarrheal agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-diarrheal agents
Study: 15919319
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ropivacaine 0.5% (0.1 mL/kg(‐1)/h(‐1)) in thoracic paravertebral block (TPVB) group
Study: 15919319
Drug: Systemic analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic analgesia with ketoprofen, paracetamol, and PCA with intravenous morphine (control group)
Study: 10086938
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment for three years
Study: 7551664
Drug: Steroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid injection without washout
Study: 7551664
Drug: Joint washout
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint washout with normal saline and steroid injection
Study: 2189077
Drug: Enalapril (increased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (increased dosage from 10 to 20 mg daily in 12 patients)
Study: 2189077
Drug: Enalapril (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (with additional antihypertensive agents in 8 patients)
Study: 26451863
Drug: TLIF in
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLIF in segment L IV/V (group 1)
Study: 26451863
Drug: TLIF in
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLIF in segment L V/S I (group 2)
Study: 21233500
Drug: Dual closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual closed-loop administration of propofol and remifentanil
Study: 23223772
Drug: Manual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual administration of propofol and remifentanil
Study: 12390612
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 mL of normal saline, 0.9% intravenously)
Study: 769156
Drug: Metiamide (Histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metiamide (Histamine H2-receptor antagonist)
Study: 30968986
Drug: ParActin® 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ParActin® 300 mg/day
Study: 30968986
Drug: ParActin® 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: ParActin® 600 mg/day
Study: 21365840
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL triamcinolone acetonide plus 0.5 mL saline (experimental group, n = 46)
Study: 21365840
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL saline solution (control group, n = 44)
Study: 15808038
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg prednisone orally for 1 or 2 days
Study: 15808038
Drug: Identical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo treatment
Study: 8585698
Drug: Phytosterol-enriched diet
Normalized name: phytosterols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterol-enriched diet (740 mg phytosterols/day)
Study: 8585698
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (29 mg phytosterols/day)
Study: 411165
Drug: SCG 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCG 2% nasal solution
Study: 26446505
Drug: Chincup therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chincup therapy
Study: 26446505
Drug: Facemask therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facemask therapy (combined with rapid palatal expansion)
Study: 17043337
Drug: Rifaximin 400
Normalized name: Rifaximin 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 400 mg 3 times daily for 10 days (n = 43)
Study: 12698083
Drug: Ursodiol, 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodiol, 800 mg per day for 12 months
Study: 8959531
Drug: roxithromycin or
Normalized name: roxithromycin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin or minocycline (oral medication) and/or nadifloxacin cream or clindamycin hydrochloride lotion (topical medication) for 1‐8 weeks
Study: 8195352
Drug: ZK 98,734
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZK 98,734 (12.5, 25, 50 or 100 mg twice daily for 4 days)
Study: 29694685
Drug: Romosozumab 210
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romosozumab 210 mg monthly (QM)
Study: 29694685
Drug: Romosozumab followed
Normalized name: romosozumab
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romosozumab followed by Denosumab 60 mg every 6 months (Q6M)
Study: 29694685
Drug: Romosozumab 210
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romosozumab 210 mg QM
Study: 22922235
Drug: Trauma-focused day-treatment
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused day-treatment group program (2 days with three nonverbal and two group psychotherapy sessions per week)
Study: 22922235
Drug: Trauma-focused day-treatment
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused day-treatment group program (same amount of sessions spread over 3 days per week)
Study: 15885789
Drug: Focal laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal laser photocoagulation combined with posterior sub-Tenon's capsule triamcinolone injection (FL + PSTI)
Study: 7671437
Drug: L-arginine i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine i.v. infusion (0.07 mmol/kg per min)
Study: 2151628
Drug: Heparan sulfate
Normalized name: heparan sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparan sulfate (200 mg, Hemovasal 100 b.i.d.)
Study: 6776858
Drug: Continuous oxygen
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oxygen (O2) therapy
Study: 6776858
Drug: Nocturnal O2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocturnal O2 therapy
Study: 25972158
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone 40 mg for days 1 to 4, oral cyclosporine 2.5 to 3 mg/kg daily for days 1 to 28, intravenous low-dose rituximab 100 mg for days 7, 14, 21, and 28.
Study: 23305576
Drug: HTK solution
Normalized name: Custodial HTK Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTK solution (16 patients)
Study: 20721895
Drug: Guided self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided self-help (GSH) treatment
Study: 17093107
Drug: Earnings supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Earnings supplement (qualifying by working full-time)
Study: 3204249
Drug: Nalmefene, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene, 20 mg
Study: 29091082
Drug: Linaclotide 72 μg
Normalized name: linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linaclotide 72 μg
Study: 29091082
Drug: Linaclotide 145 μg
Normalized name: linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linaclotide 145 μg
Study: 23618489
Drug: Daily Iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Iron and Folic Acid Supplementation
Study: 23618489
Drug: Weekly Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly Iron and Folic Acid Supplementation
Study: 21948069
Drug: Propofol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (4 mg/kg loading dose administered intravenously)
Study: 10795647
Drug: Budesonide aqueous
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide aqueous nasal spray (256 microg daily)
Study: 10795647
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate nasal spray (200 microg daily)
Study: 1450046
Drug: rIFN‐alpha 2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN‐alpha 2a (3 MU/m2 s.c. three times weekly for 6 months)
Study: 1450046
Drug: rIFN‐alpha 2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN‐alpha 2a (3 MU/m2 five days/week for an additional 6 months after chemotherapy)
Study: 1450046
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rIFN‐alpha 2a, streptozocin (2 g), and doxorubicin (40 mg/m2)
Study: 6483935
Drug: Diazepam 0.2
Normalized name: diazepam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.2 mg/kg (oral administration)
Study: 6483935
Drug: Diazepam 0.2
Normalized name: diazepam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.2 mg/kg (intravenous administration)
Study: 26605836
Drug: Aflibercept (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept (2.0 mg, 0.05 mL intravitreous injections)
Study: 26605836
Drug: Bevacizumab (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (1.25 mg, 0.05 mL intravitreous injections)
Study: 26605836
Drug: Ranibizumab (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.3 mg, 0.05 mL intravitreous injections)
Study: 9654837
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of proglumide with one-half analgesic dose
Study: 9654837
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with full analgesic dose
Study: 8605516
Drug: Carbohydrate-electrolyte (CE)
Normalized name: CARBOHYDRATE/ELECTROLYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-electrolyte (CE) solution (6.9% providing 1.0 g CHO.kg body weight‐1)
Study: 8605516
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (control group)
Study: 29240021
Drug: Increasing electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increasing electrical dosage
Study: 29240021
Drug: Increasing MST
Normalized name: MST 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing MST dosage
Study: 28676038
Drug: Oral sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sildenafil for 16 weeks
Study: 19632969
Drug: 9 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9 weeks of immediate-program-access as an add-on to treatment-as-usual (N = 320)
Study: 19632969
Drug: 9-week delayed-access
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9-week delayed-access plus treatment-as-usual (N = 76)
Study: 16861168
Drug: Qi therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qi therapy without touching (QTN)
Study: 16861168
Drug: Qi therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qi therapy with touching (QTT)
Study: 12638397
Drug: Wood creosote
Normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wood creosote 45 mg
Study: 12638397
Drug: Wood creosote
Normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wood creosote 90 mg
Study: 12638397
Drug: Wood creosote
Normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wood creosote 135 mg
Study: 12638397
Drug: Wood creosote
Normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wood creosote 180 mg
Study: 12638397
Drug: Wood creosote
Normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wood creosote 225 mg
Study: 10713659
Drug: CHOP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP plus high-dose tamoxifen (Group II)
Study: 27138020
Drug: Subcutaneous suction
Normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous suction drain (SD)
Study: 27138020
Drug: No subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No subcutaneous suction drain (no SD)
Study: 10358788
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine 2 mg kg‐1 hr‐1 and fentanyl 5 micrograms kg‐1 hr‐1 for the first 60 min and 3 micrograms kg‐1 hr‐1 for the next 90 min, and droperidol 0.1 mg kg‐1 (Group A)
Study: 10358788
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine 2 mg kg‐1 hr‐1, droperidol 0.1 mg kg‐1 and fentanyl 50‐100 micrograms in a bolus intermittently as needed (Group B)
Study: 7579383
Drug: Sequential IL-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential IL-3 and GM-CSF (schedule B)
Study: 7579383
Drug: Concurrent IL-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent IL-3 and GM-CSF
Study: 1979272
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg dimetindene maleate
Study: 1979272
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride solution (placebo)
Study: 6767576
Drug: Brompheniramine maleate
Normalized name: Brompheniramine Maleate
DrugBank: Brompheniramine (DB00835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brompheniramine maleate (antihistamine)
Study: 28423931
Drug: Enhanced walking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced walking program (incentives, feedback, competitive challenges, monthly wellness workshops)
Study: 28423931
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in average daily steps
Study: 22302614
Drug: GeniVida™ bone
Approvals — FDA: no, EMA: no, PMDA: no
Description: GeniVida™ bone blend (GBB) - genistein (30 mg/day), vitamin D3 (800 IU/day), vitamin K1 (150 μg/day), polyunsaturated fatty acids (1 g/day)
Study: 21462082
Drug: Selenium-enriched yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium-enriched yeast (247 μg/day for 9 months)
Study: 18282776
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement therapy, starting dose 0.003 mg/kg/day for 8 weeks, then adjusted based on serum IGF-I levels
Study: 16433867
Drug: Ivabradine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine (30 mg)
Study: 11061579
Drug: Cerivastatin 0.8
Normalized name: cerivastatin 0.8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.8 mg with itraconazole 200 mg
Study: 11061579
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg with itraconazole 200 mg
Study: 11061579
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg with itraconazole 200 mg
Study: 20175283
Drug: 0.25% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% levobupivacaine (Group L, n = 30)
Study: 17971487
Drug: R-DHAP (rituximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-DHAP (rituximab + DHAP chemotherapy)
Study: 17971487
Drug: DHAP (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHAP (chemotherapy without rituximab)
Study: 15948814
Drug: Immediate-release omeprazole
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate-release omeprazole (bedtime dosing)
Study: 15948814
Drug: Pantoprazole (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (once daily predinner dosing)
Study: 15948814
Drug: Pantoprazole (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (twice daily prebreakfast and bedtime dosing)
Study: 15948814
Drug: Immediate-release omeprazole
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate-release omeprazole (twice daily dosing 20 and 40 mg)
Study: 15948814
Drug: Immediate-release omeprazole
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate-release omeprazole (40 mg bedtime dosing)
Study: 15948814
Drug: Pantoprazole (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (twice daily dosing 40 mg)
Study: 8678062
Drug: Anticoagulant citrate
Normalized name: ANTICOAGULANT CITRATE DEXTROSE
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anticoagulant citrate dextrose-A (ACD) (0.113 mol/L citrate)
Study: 8678062
Drug: Hypertonic tri-sodium
Normalized name: alginic acid
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic tri-sodium citrate (TSC) (1.6 mol/L citrate)
Study: 6401229
Drug: Oral isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral isosorbide dinitrate (ISDN) and topical 2% nitroglycerin ointment (NO)
Study: 24174275
Drug: landiolol hydrochloride
Normalized name: Landiolol Hydrochloride
DrugBank: Landiolol (DB12212)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: landiolol hydrochloride 0.125 mg/kg
Study: 22770832
Drug: Readiness to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Readiness to change behavior for 2 daily servings of milk
Study: 22770832
Drug: Readiness to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Readiness to change behavior for 4 daily servings of milk
Study: 16243988
Drug: Granisetron 0.1
Normalized name: granisetron 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 0.1 mg plus Dexamethasone 8 mg (G+D)